Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer

To improve the survival in patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) by loco-regional therapy with personalized ultra-fractionated radiation plus immunotherpy.

Trial Details

NCT ID
NCT06841159
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Ultra-fractionated radiation therapy
  • Sintilimab
  • Standard systemic therapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Patient is 18-75 years old at the time of signing the informed consent form.
  • ECOG performance status 0-1.
  • Histopathological confirmed MSS/pMMR adenocarcinoma of the colon or rectum.
  • Distant metastasis lesions are no more than 10 and all sites of disease can be safely treated based on a pre-plan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →